(PharmaNewsWire.Com, July 19, 2017 ) RNA interference is a process in which RNA inhibits the gene expression, by degrading mRNA molecules. It is also called Gene silencing. Recently, we are sending artificial drugs to carry out these functions and that process is called RNAi Drug Delivery.
RNAi Drug Delivery is an unfolding therapeutic method. This method has fewer side effects and is specific to the point. We can cure cancer with this method by controlling gene mutation. From 2006, onwards numerous clinical tests are being held and people are investing billions in this market to approve and research various types of RNAi-based Drugs.
Few factors like Increasing incidence of chronic diseases like cancer and cardiovascular diseases, and innovative Applications of drug delivery market are driving this market. In addition, Research carried out in RNA Therapeutic field has also fueled the growth in Latin America RNA Drug Delivery Market. But, High investments and stringent Regulations are some of the major restraints to this market. Targeted Delivery of RNAi Drugs is the key challenge faced by the market. Availability of advanced technology here compared to developed regions is low which is restraining the market’s growth.
Latin America RNAi Drug Delivery market is segmented based on Drug Delivery and Therapeutic Application. Based on Drug Delivery, this market is further segmented into pulmonary drug delivery technology, aptamer drug delivery technology, nucleic acid drug delivery technology and nanoparticle drug delivery technology. Based on Therapeutic Application, the market is further segmented into cardiology, metabolic disorders, oncology, ophthalmology, infectious diseases and neurology.
Based on Geography, this market is further segmented into Brazil, Argentina and Mexico. This region has the high CAGR because of increased investments by key players in this region.
Key players in this region are Alnylam Pharmaceuticals Inc., Merck & Co. Inc, Dicerna Pharmaceuticals Inc., Tekmira Pharmaceuticals Corp., Access Pharmaceuticals Inc., Sirnaomics Inc., Isis Pharmaceuticals Inc, RXi Pharmaceuticals Corp., Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Silence Therapeutics plc, Traversa Therapeutics Inc., Marina Biotech Inc., Tacere Therapeutics Inc., and PhaseRx Inc.
About Market Data Forecast:
The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering North America among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
